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Epican, a heparan sulfate proteoglycan, was recently identi-
fied on the surface ofkeratinocytes with the aid of a monoclo-
nal antibody to its core protein. Using that antibody to screen 
a human keratinocyte eDNA library, a clone encoding the 
entire epican core protein was selected and sequenced. The 
core protein of epican is a form of CD44. The deduced pro-
C ell-surface proteoglycans have roles in cvtoskeletal-matrix interactions, cell-cell adhesion, growth factor binding, and signal transduction [1,2]. Although some of these functional characteristics are mediated by the glycosaminoglycan chains and others by the 
core protein, proteoglycans are increasingly classified according to 
similarities in core protein sequence. 
We recently identified a large, cell-surface, heparan sulfate prote-
oglycan that was present on epithelial but not mesenchymal cells in 
the skin [3] . A monoclonal antibody, MoAb17, was used to demon-
strate that the intact proteoglycan had an Mr of> 250 kDa and the 
degl ycosylated core protein had an apparent Mr of 180 kDa. West-
ern immunoblots of keratinocyte proteoglycans, using antibodies 
against known core proteins of cell-surface proteoglycans, indicated 
that MoAb 17 recognized a proteoglycan that might be a member of 
the CD44 family of glycoproteinsjproteoglycans. 
CD44 is the most widely used designation for a family of cell-
surface molecules expressed on hematopoietic, mesenchymal, and 
epithelial cells [4-7]. CD44 is the antigen recognized by monoclo-
nal antibodies, including 515 [4], FI0.44.2 [5], AIG3 [6], Hermes 
1-3 [7], and Hutch-l [8] . Functional characteristics, such as roles in 
lymphocyte homing [4,9], lymphocyte activation [10] , homotypic 
[10-13] and heterotypic [9 ,14) cell-cell adhesion, cell-matnx-
cytoskeletal interactions [15,16], and hyaluronate binding [17,18], 
account for other designations based on antigen reactivity, e.g., 
Hermes antigen [19]; cell of origin, e.g., phagocytic glycoprotein-l 
(Pgp-l) [20]; or function, e.g., hyaluronate receptor [17,18] hom-
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tein sequence of 699 amino acids has a novel 339 amino acid 
domain inserted into the proximal extracellular domain of 
the standard, leukocyte form of CD44. The additional do-
main adds a number of potential N- and O-linked glycosyla-
tion sites and two proteolysis sites to this form of CD44. ] 
Invest Dermatol 99:381-385, 1992 
ing-cell adhesion molecule (H-CAM) [21] and extracellular matrix 
receptor III [15]. 
There is striking molecular heterogeneity within the CD44 fam-
ily, despite the apparent derivation of all the members from a single 
copy gene on chromosome 11 ([22], unpublished data summarized 
in [23]). Nucleotide sequences for human [23,24]' mouse [25-27]' 
baboon [28], and rat [29] CD44 indicate phylogenetic conservation 
of the N-terminal and transmembrane portions of the predicted 
protein. Sequence data from a variety of tissues [21,30 - 34J indicate 
that alternative mRNA splicing is an important source ofheteroge-
neity within the extracellular and cytoplasmic domains of the 
human CD44 family. Additional size heterogeneity in the CD44 
family can be attributed to a variety of N- and O-linked glycosyla-
tions, including the addition of chondroitin sulfate [19] and heparan 
sulfate [31]. 
In order to further characterize and appropriately classify the 
heparan sulfate proteoglycan identified by MoAb 17, we obtained a 
deduced protein sequence for its core protein using MoAb 17 to 
screen.a kerati~ocyte cDNA expression library. We report here that 
the eplder.mall~tercellular proteoglycan, which we had tentatively 
named eplcan, 1S a member of the CD44 family. 
MATERIALS AND METHODS 
Isolation of cDNA Clones A Agtll cDNA library from normal 
human foreskin keratinocytes was generously provided by John 
Stanley, NIH, Bethesda, MD [35]. Immunoscreening of phage 
pla.ques on a lawn of Escherichia coli Y1090 was performed as de-
scnbed by Hunyh et al [36]. Briefly, nitrocellulose filters impreg-
nated with 10 mM isopropylthiogalactoside were placed over a bac-
terial lawn and incubated for 211 at 37°C. The filters were then 
incubated with MoAb17 [3] (hybridoma supernatant at a 1 : 10 dilu-
tion). An alkaline phosphatase-conjugated rabbit anti-mouse IgG 
(Protoblot Kit, Promega Biotec, Madison, WI) was used as the 
second antibody. Following plaque purification of positive clones, 
cDNA inserts were excised by digestion with EcoR1 and subcloned 
into pBluescript (Stratagene, La Jolla, CA). 
~NA Sequence Determi~ation and Analysis DNA sequenc-
111~ was perfo:med by the dldeoxy-chain-termination method [37] 
uS1l1g a mod1fied T7 polymerase (Sequenase, US Biochemicals 
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Corp., Cleveland, OH). Nucleotide sequence was determined from 
restriction fragments subcloned into pBluescript and from nested 
sets of deletions generated by exonuclease III (Promega Biotec) at 
3D-second time intervals according to the method of Henikoff [38], 
or by using oligonucleotide primers synthesized on the basis of 
preceding sequences. DNA sequence was determined for both 
strands throughout the coding region. 
Northern Blot Analysis Total cellular RNA was isolated from 
cultured cells as described by Chirgwin et al [39]. PolyA+ mRNA 
was prepared by chromatography over oligo (dT)-cellulose [40]. 
Twenty micrograms of RNA or 2-3 J.1.g of poly A+ RNA was elec-
trophoresed through a 1 % agarose gel containing 2.2 M formalde-
hyde, and transferred to 0.2 J.1. nitrocellulose. Probes for Northern 
blot analysis were derived either from the entire cDNA or synthe-
sized by polymerase chain reaction (PCR) in a DNA thermal cycler 
(Perkin-Elmer Cetus Corporation, Norwalk, CT) using Thermus 
aquaticus (Taq) DNA polymerase and oligonucleotide primers of 
known sequence flanking the region of interest. Reaction condi-
tions were as follows: 40 cycles of 1'15" at 94°C, 1'15" at 55°C, 
and 2'15" at 73 °C. The reaction products obtained by PCR were 
separated by agarose gel electrophoresis; individual bands were ex-
cised and the DNA isolated by Gene Clean (Bio 101, LaJolla, CAl· 
Probes were labeled by extension using Klenow fragment of DNA 
polymerase I in the presence of [a_32P]dCTP [41]. mRNA sizes 
were determined relative to ethidium bromide - stained markers 
(Bethesda Research Laboratories). Hybridization was performed at 
42°C in 5 )< SSC, 5 X Denhardt's 100 J.1.g/ml denatured salmon 
sperm DNA, 0.1 % sodium dodecylsulfate (SDS) and 50% forma-
mide. The membranes were washed to a final stringency of 0.1 X 
SSC and 0.1 % SDS at 56 0 C and exposed to Kodak XAR-5 film for 
autoradiography. 
RESULTS 
Isolation of cDNA Clones Expressing the MoAb17 Epi-
tope Nine positive clones were identified using MoAb 17 to 
screen approximately 8 X lOs plaques from a human keratinocyte 
Agtl1 expression library. Five clones were plaque purified and 
found to contain inserts ranging from 2.0-2.5 kb. Each insert hy-
bridized to each of the others, suggesting that they were all closely 
related. Therefore, only the insert in one clone (pKG 1) was fully 
sequenced. 
Sequence of Clone pKG 1 The complete sequence of the cD N A 
insert in pKG 1 and the deduced amino acid sequence are shown in 
Fig 1. The clone includes 2265 base pairs, which contain an open 
reading frame of2097 nucleotides that begins with an ATG at base 
130. This sequence predicts a protein of 699 amino acids with a 
molecular mass of78,890. Comparison of the pKG 1 insert sequence 
with those in the GenBank and EMBL data bases indicated that 
pKG 1 is a form of CD44. The sequence of pKG 1 can be compared 
to other recently identified alternative forms of CD44 with the aid 
of numbers (1- 7) in Fig 1 that indicate presumed splice junctions. 
pKG 1 contains the entire coding sequence and the same 3' and 5' 
untranslated regions of the human, leukocyte CD44 identified by 
Stamenkovic et al [24]. Two conservative nucleotide differences 
were found in th.e region of the coding sequence: a T to C substitu-
tion at nucleotide 384, and an A to G substitution at nucleotide 
1858. Within the CD44 sequence, pKGl also contains a 1017 
nucleotide sequence (between junctions 1 and 6 in Fig 1) that is 
nearly identical to PCR products identified from mRNA in several 
cell lines [34] . The differences are a conservative C to T substitution 
at nucleotide 942, and two non-conservative changes-an A to T 
substitution at nucleotide 1229, which converts a glutamic acid to a 
valine, and a G to A substitution at 1250, which converts an arginine 
to a lysine. When the 4-6 domain is independently expressed (see 
below), the first predicted amino acid in that domain is asparagine 
[30 - 32]; when expressed as part of the 1- 6 domain, that asparagine 
becomes aspartic acid in our sequence and in tumor cells [34]. 
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Predictions from the Deduced Protein Sequence The Kyte-
Doolittle hydropathy plot [42] in Fig 2a identifies hydrophobic 
regions that correspond to the presumed signal and transmembrane 
sequences in the predicted protein. These regions are marked on the 
linear representation of the predicted protein in Fig 2b. The re-
mainder of the extracellular domain is generally hydrophilic. One 
notable feature is that the deduced peptide from region 1 - 3 has a 
predicted pI of3.67 compared to a pI of5.06 for the entire molecule. 
Sites for potential post-translational modification of the deduced 
protein are indicated in Fig 2b. All forms of CD44 are heavily 
glycosylated. The additional extracellular domain predicted by the 
1- 6 alternative sequence adds three potential N-glycosylation sites, 
several clusters of O-glycosylation sites, and two potential chon-
droitin sulfate attachment sites. Two potential proteolytic cleavage 
sites are introduced into the extracellular domain by the 1 - 6 insert. 
The predicted protein sequence yields a molecule less than half 
the size estimated from the mobility of deglycosylated protein on 
SDS-polyacrylamide gel electrophoresis (PAGE) (79 kDa versus 
180 kDa). Similar results have been observed with deglycosylated 
proteoglycans, which have large regions of charged amino acids 
[43]. Thus the difference in molecular size probably represents 
anomalous migration on SDS-PAGE of these molecules. However, 
we have not eliminated post-translational modifications other than 
glycosylations as the cause of slow migration in the gel. 
Hybridization Analysis Six of the original nine clones that had 
been identified by immunoscreening with MoAb 17 were probed 
with the 1 - 6 domain from the pKG 1 insert. All hybridized to the 
1 - 6 insert. Three of those, determined to be independent clones on 
the basis of partial sequencing of their 3' and 5' ends, also hybridized 
to a probe consisting of the 1 - 3 sequence. Thus, at least three 
independent clones of CD44 contained the 1 - 3 domain, indicating 
that MoAb 17 consistently identified forms of CD44 with this in-
sert. 
RNA from several cell types was probed with both the entire 
pKG 1 insert and segments of the 1-6 sequence. RNA from human 
keratinocytes as well as human fibroblasts hybridized to the entire 
pKG 1 probe (Fig 3a). The major hybridizing transcripts in keratino-
cytes were larger than those in fibroblasts, as previously noted [31]. 
By contrast, RNA from keratinocytes, but not fibroblasts, hybrid-
ized to probes made from the 1-6 (Fig 3b), the 1-4 (Fig 3c), and the 
1 - 3 (Fig 3d) sequences. 
DISCUSSION 
CD44 is a family of transmembrane glycoproteins and proteogly-
cans whose remarkable heterogeneity arises from a combination of 
alternative splicing of a single gene transcript and variable post-
translational modifications. Core protein sequences, deduced from 
cDNA cloning or PCR amplification of mRNA, reveal that all 
members of the family share two domains: a domain near the N -ter-
minal, which is homologous with cartilage link protein, and a prox-
imal extracellular/transmembrane domain. Different core proteins 
could arise from alternative mRNA splicing: two alternative forms 
of the intracellular, C-terminal domain [21], and at least five alter-
native forms of the extracellular domain have been predicted 
[21,29 - 34]. Cell-specific splicing can be inferred from PCR analy-
sis of mRNA [29-31]' but there is limited information about the 
actual glycoprotein/proteoglycan product of each splice variant. 
The form of CD44 that we have identified in a cDNA library 
from normal human keratinocytes contains all previously described 
protein-coding sequences of CD44 in a single mRNA. The junc-
tions for all the previously reported, alternative protein-coding se-
quences have been given a numerical designation (1- 7) in Figs 1 
and 2. Alternative forms of the CD44 core protein can have a trun-
cated cytoplasmic domain at junction 7 and contain all, none, or 
some of the sequences between junctions 1 and 6. Thus, the leuko-
cyte form has none of the sequences between 1 and 6 but can have a 
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CGGCCCAGCGGACCCCAGCCTCTGCCAGGTTCGGTCCGCCATCCTCGTCCCGTCCTCCGCCGGCCCCTGCCCCGCGCCCAGGGATCCTCCAGCTCCTTTCGCCCGCGCCCTCCGTTOGCT 120 
CCGGACACCATGGACAAGTTTTGGTGGCACGCAGCCTGGGGACTCTGCCTCGTGCCGCTGAGCCTGGCGCAGATCGATTTGAATATAACCTGCCGCTTTGCAGGTGTATTCCACGTGGAG 240 
MDKFWWHAAWGLCLVPL SLAQIDL NITC RFAGVF HVE 
AAAAATGGTCGCTACAGCATCTCTCGGACGGAGGCCGCTGACCTCTGCAAGGCTTTCAATAGCACCTTGCCCACAATGGCCCAGATGGAGAAAGCTCTGAGCATCGGATTTGAGACCTGC 360 
38 K N G R Y S SRTEAADLCKAF N STLPT M AQ ME KALSIGFETC 
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AGGTATGGGTTCATAGAAGGGCACGTGGTGATTCCCCGGATCCACCCCAACTCCATCTGTGCAGCAAACAACACAGGGGTGTACATCCTCACATCCAACACCTCCCAGTATGACACATAT 
RYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTY 
TGCTTCAATGCTTCAGCTCCACCTGAAGAAGATTGTACATCAGTCACAGACCTGCCCAATGCCTTTGATGGACCAATTACCATAACTATTGTTAACCGTGATGGCACCCGCTATGTCCAG 
C FNA SAPPE EDCT SVTDLPNAFDGPI T ITIVNRDGTRYVQ 
AAAGGAGAATACAGAACGAATCCTGAAGACATCTACCCCAGCAACCCTACTGATGATGACGTGAGCAGCGGCTCCTCCAGTGAAAGGAGCAGCACTTCAGGAGGTTACATCTTTTACACC 
KGEYRTNPEDIYPSNPTDDDVSSGSSSERSSTSGGYIFYT 
1 2 
TTTTCTACTGTACACCCCATCCCAGACGAAGACAGTCCCTGGATCACCGACAGCACAGACAGAATCCCTGCTAC~GTACGTCTTCAAATACCATCTC1F.CAGGCTGGGAGCCAAATGAA 
F 5 T V H PIP 0 E 0 5 P WIT 0 5 TOR I PAT 5 T 5 5 N TIS A G W E P N E 
3 
GAAAATGAAGATGAAAGAGACAGACACCTCAGTTTTTCTGGATCAGGCATTGATGATGATGAAGATTTTATCTCCAGCAC9r.TTTCAACCACACCACGGGCTTTTGACCACACAAAACAG 
ENEDERDRHLSFSGSGIDDDEDFISSTISTTPRAFDHTKQ 
AACCAGGACTGGACCCAGTGGAACCCAAGCCATTCAAATCCGGAAGTGCTACTTCAGACAACCACAAGGATGACTGATGTAGACAGAAATGGCACCACTGCTTATGAAGGAAACTGGAAC 
N Q 0 W T Q W N P 5 H 5 N P E V L L Q T T T R M T 0 V 0 R N G T T AYE G N W N 
CCAGAAGCACACCCTCCCCTCATTCACCATGAGCATCATGAGGAAGAAGAGACCCCACATTCTACAAGCACAATCCAGGCAACTCCTAGTAGTACAACGGAAGAAACAGCTACCCAGAAG 
PEA H P P L I H H E H H E E E E T PHS T 5 T I QAT P SST TEE T AT Q K 
GAACAGTGGTTTGGCAACAGATGGCATGTGGGATATCGCCAAACACCCAAAGAAGACTCCCATTCGACAACAGGGACAGCTGCAGCCTCAGCTCATACCAGCCATCCAATGCAAGGAAGG 
E Q W F G N R W H V G Y R Q T P KED 5 H 5 T T G T A A A 5 A H T 5 H P M Q G R 
4 
ACAACACCAAGCCCAGAGGACAGTTCCTGGACTGATTTCTTCAACCCAATCTCACACCCCATGGGACGAGGTCATCAAGCAGGAAGAAGGAT~ATATGGACTCCAGTCATAGTACAACG 
T T P 5 P E 0 5 S W T D F F N PIS H P M G R G H Q A G R R M b M 0 5 5 H 5 T T 
CTTCAGCCTACTGCAAATCCAAACACAGGTTTGGTGGAAGATTTGGACAGGACAGGACCTCTTTCAATGACAACGCAGCAGAGTAATTCTCAGAGCTTCTCTACATCACATGAAGGCTTG 
L Q PTA N P N T G L V E 0 L D R T G P L 5 M T T Q Q 5 N 5 Q 5 F 5 T 5 H E G L 
5 
GAAGAAGATAAAGACCATCCAACAACTTCTACTCTGACATCAAG~TAGGAATGATGTCACAGGTGGAAGAAGAGACCCAAATCATTCTGAAGGCTCAACTACTTTACTGGAAGGTTAT 
E E 0 K 0 H P T T 5 T L T S 5 ~ R N D V T G G R R 0 P N H 5 E G 5 TTL LEG Y 
ACCTCTCATTACCCACACACGAAGGAAAGCAGGACCTTCATCCCAGTGACCTCAGCTAAGACTGGGTCCTTTGGAGTTACTGCAGTTACTGTTGGAGATTCCAACTCTAATGTCAATCGT 
T 5 H Y P H T K E 5 RTF P V T S A K T G 5 F G V T A V T V G 0 5 N 5 N V N R 
6 
TCCTTATCAGGAbACCAAGACACATTCCACCCCAGTGGGGGGTCCCATACCACTCATGGATCTGAATCAGATGGACACTCACATGGGAGTCAAGAAGGTGGAGCAAACACAACCTCTGGT 
5 L 5 G b Q 0 T F H PSG G S H T T H G S 0 S 0 G H S H G S Q EGG ANT T S G 
7 
CCTATAAGGACACCCCAAATTCCAGAATGGCTGATCATCTTGGCATCCCTCTTGGCCTTGGCTTTGATTCTTGCAGTTTGCATTGCAGTCAACAGTCGAAGNAGGTGTGGGCAGAAGAAA 
P I R T P Q I PEW L I I LA S L L A L A L I L A V C I A V N S R R ~ C G Q K K 
AAGCTAGTGATCAACAGTGGCAATGGAGCTGTGGAGGACAGAAAGCCAAGTGGACTCAACGGAGAGGCCAGCAAGTCTCAGGAAATGGTGCATTTGGTGAACAAGGAGTCGTCAGAAACT 
K L V INS G N G A V E 0 R K PSG LNG E ASK 5 Q E M V H L V N K E SSE T 
CCAGACCAGTTTATGACAGCTGATGAGACAAGGAACCTGCAGAATGTGGACATGAAGATTGGGGTGTAACACCTACACCATTATCTTGGAAAGAAACAACCGTTG 
PDQ F M TAD E T R N L Q N V 0 M K I G V • 
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Figure 1. Nucleotide and deduced amino acid sequences for a keratinocyte form of CD44. Clone pKG 1 was selected from a normal human keratinocyte 
cDN A express ion library using monoclonal antibody MoAb17 and then sequenced as described in Materials alld Metlrods. The 5' portion of the sequence (up to 
base 795) and the 3' portion (resuming at base 1813) are nearly identical to the leukocyte form of CD44 [24]. The sequence between bases 796 and 1812 has 
been identified recently in tumor cells [34]. Numbered vertical bars, sites where alternative sequences of CD44 begin or end (see text). 
full-leng th or truncated cytoplasmic tail [21). A form of CD44 
containing sequences between junctions 4 and 6 has been identified 
b y PCR screening of mRNA from keratinocytes [30-32,34) and 
one containing only the sequence between 5 and 6 has been found in 
h ematopoietic cells [32) . Another form of CD44 containing se-
quences between junctions 3 and 4 has been identified in metastatic, 
but not non-metastatic, rat pancreatic tumor cells [29). A form of 
CD44 nearly identical to our 1-6 sequence was identified in several 
human tumor cell lines and reported while this manuscript was in 
preparation [34) . No normal cells were examined in that study, but 
rnRNA from transformed human keratinocytes contained a 2-6 
sequence. Curiously, those transformed keratinocytes apparently 
lacked the 24 nucleotides in the 1- 2 sequence that was found in the 
tumor cells and that we have now found in normal keratinocytes. 
Keratinocytes express several forms of CD44. Previous PCR anal-
yses of mRNA [21,31,34) had suggested that keratinocytes would 
express the leukocyte form of CD44 and at least one alternative core 
protein form of CD44. The two distinct cDNA sequences reported 
here and by Brown et al [31) indicate that, in addition to the leuko-
cyte form of CD44, two alternative core protein forms of CD44 are 
found in normal keratinocytes. Moreover, post-translational modifi-
cation of CD44 made by keratinocytes is substantial [3,31) . 
Whether the post-translational modification of each alternative 
core protein is uniform or variable remains to be determined. 
Extensive glycosylation adds to the structural heterogeneity in 
the CD44 family. All forms of CD44 contain many potential N-
and O-glycosylation sites. The leukocyte form of CD44, which 
lacks any portion of the 1 - 6 sequence, contains 15 kDa ofN -linked 
sugar and 15 kDa of O-linked sugar [19). Occasionally this form 
also contains chondroitin sulfate [19). None of the leukocyte forms 
contains heparan sulfate. 
Epithelial forms of CD44 have been reported to contain heparan 
sulfate as well as N-linked sugars and perhaps keratan sulfa te [31). 
Yet it had not been possible, previously, to identify which alterna-
tive form of the CD44 core protein carried the heparan sulfate [31). 
It is now clear, based on the sequence data presented above and the 
imrnunoblotting data in the preceding paper [3], that the largest 
alternative core protein form of CD44 is expressed as a heparan 
sulfate proteoglycan by keratinocytes. It is not known whether the 
heparan sulfate is added to the 1-6 domain or to some other portion 
of the protein. The role of cell-specificity in mRNA splicing and 
glycosylation of CD44, as well as the role of different exons in 
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Figure 2. Predicted features of the keratinocyte form of CD44. a) Kyte-Doolittle hydropathy plot of the 699 amino acid, mostly hydrophilic protein. A linear 
representation of the protein in b shows location of hydrophophic domains consistent with a signal sequence (- ) and a transmembrane domain (_ ). A 
domain homologous to cartilage link protein is dotted ( . . . ). Domains where alternative core protein sequences have been predicted are indicated by opw bars. 
N llmbered dowII arrows, junctions where previously identified alternative forms begin or end. Consensus sequences identify sites of potential post-translational 
modification: N-glycosylation (_ ), O-glycosylation (_ ), chondroitin sulfate attachment (_ ), phosphorylation (- ), and proteolysis (_ ). There is no established 
consensus sequence for heparan sulfate; therefore the site of its addition to this protein cannot be predicted. 
determining glycosylation patterns of CD44, are potentially im-
portant, unresolved issues. For example, it will be interesting to 
determine whether tumor cells that contain the mRNA for the 1-6 
alternative form express it as a heparan sulfate proteoglycan. 
Post-translational modifications, in addition to glycosylations, 
have been found on CD44. Sulfation of the core glycoprotein has 
been described [19] . Phosphorylation of CD44 [1 6] and the mouse 
homologue of CD44, Pgp- l [15], have been reported. Two poten-
tial phosphorylation sites are present in the cytoplasmic domain of 
both the mouse [27] and human protein (see Fig 2). Although the 
predicted sequence of mouse Pgp-l is only 72% identical to human 
CD44, the location and sequence of sites for potential phosphoryla-
tion by protein kinase C and by a cAMP / cGMP-dependent protein 
kinase are precisely conserved. 
Soluble forms ofCD44 have been found in blood of mice [44] and 
in culture medium from human keratinocytes [3] . Dibasic peptide 
sites for potential proteolysis exist in CD44 from both species. The 
murine form of CD44 has a single Arg.Arg site in the proximal 
extracellular domain. The human forms of CD44 have lost that site, 
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Figure 3. Northern blot hybridizations using the different portions of 
pKG1. Poly A + RNA from cultured human keratinocytes (K) and fib roblasts 
(DF) was hybridized to the entire 2265 base clone (a), the 1-6 sequence (b), 
the 1-4 sequence (c), and the 1- 3 sequence (d). Kilobase markers are on the 
left side of the panel. 
due to a single base change (G > C at base 1931 in our sequence, 
which changes Arg to Thr). Two new potential proteolysis sites are 
introduced into human forms containing the 3 - 4 and 5 - 6 se-
quences. Thus, alternative forms of human CD44 will be differen-
tially susceptible to proteolysis. This may have further significance, 
because proteolysis of cell-surface proteoglycans has been proposed 
as a mechanism for regulating growth-factor activity [45,46]. Two 
other integral membrane proteoglycans, syndecan [47] and betagly-
can [45] , have extracellular proteolytic cleavage sites and are known 
to bind growth factors. 
The discovery of alternative core protein forms of CD44 raises 
many questions about the role of the additional sequences in modu-
lating function. The CD44 form containing the 4-6 domain has 
reduced ability to bind hyaluronic acid [30] when compared to 
CD44 lacking that domain. A CD44 form containing the 3 - 4 
domain confers new metastatic potential when transfected into 
otherwise non-metastasizing tumor cells [29]. The functional con-
sequences of expressing the entire 1- 6 domain or of expressing 
several CD44 forms simultaneously are unknown but intriguing. 
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